Alpha Tau Medical
School of Physics, Suite 323
Tel Aviv University, P.O. Box 39040
About Alpha Tau Medical
Alpha Tau Medical is an Israeli medical device company that focuses on research, development and commercialization of Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) for the treatment of solid cancer. The Alpha DaRT technology was developed in 2003 at Tel Aviv University.
CEO and Chairman: Uzi Sofer
CTO: Professor Itzhak Kelson, Ph.D.
Chief Biomedical Officer: Professor Yona Keisari, Ph.D.
11 articles with Alpha Tau Medical
Medison Pharma and Alpha Tau Medical Announce a Collaboration in the Oncology Field in Central and Eastern Europe
Medison Pharma Trading AG, a fully owned subsidiary of Medison Pharma Ltd., and Alpha Tau Medical Ltd., the developer of a breakthrough alpha-radiation cancer therapy "Alpha DaRT," are pleased to announce an exploratory collaboration in the oncology field in Central and Eastern Europe.
Alpha Tau Medical, the developer of breakthrough alpha-radiation cancer therapy Alpha DaRT, is pleased to announce the closing of a Series B equity financing of $26 million.
Alpha Tau Medical Announces Exclusive Distribution Arrangement With Medison Canada for Breakthrough Cancer Treatment Alpha DaRT
Alpha Tau Medical – the developer of breakthrough alpha-radiation cancer therapy Alpha DaRT, and Medison Canada – a fully owned subsidiary of Medison Pharma, are pleased to announce that they have entered into an exclusive distribution arrangement. Medison is a specialized pharmaceutical and biotech company purely focused on lice
The cancer biotech company Alpha Tau Medical, announced the appointment of Prof. Yona Keisari as Chief Scientific Officer.
9/6/2019Biopharma companies strengthen the C-suite and board of directors with these appointments.
Alpha Tau Medical Appoints Jefferson University Radiation Oncologist Robert Den as Chief Medical Officer
Alpha Tau Medical announced the appointment of Dr. Robert B. Den, MD, as Chief Medical Officer (CMO). In his new role, and as a prominent expert and accomplished clinician, Dr. Den will lead the clinical research functions for Alpha Tau, furthering the company mission of innovation in cancer therapy.
Breakthrough Cancer Therapy Developer, Alpha Tau, Awarded ISO 13485 Certificate for Quality Management of Medical Devices
Alpha Tau Medical, developer of the breakthrough alpha radiation cancer therapy, Alpha DaRT, announced that it has obtained ISO 13485:2016 certification.
Cancer Biotech Firm Alpha Tau Medical Appoints Raphi Levy of Goldman Sachs as Chief Financial Officer
Mr. Levy will focus primarily on driving business growth, leveraging his unique experience and long-standing international relationships, to support strategic private and public fundraising, advance company strategy and expand collaborations with leading enterprises worldwide.
Alpha Tau Medical Launches New Clinical Trials in Italy with Leading Cancer Centers, La Sapienza and IFO
Trials will investigate the efficacy of its breakthrough cancer treatment, Alpha DaRT, in Squamous Cell Carcinoma (SCC) of the Skin, and Cutaneous and Mucosal malignant Neoplasia (CMN)
Proceeds to accelerate expansion of global clinical research program and establish new production facilities to meet growing demand for the company's breakthrough cancer treatment, Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy).
Alpha Tau's High-Precision Cancer Radiotherapy Receives Radioactive-Safety Approval in the United States
Israel MedTech startup, Alpha Tau Medical, is proud to announce that the Massachusetts Radiation Control Program (RCP), under agreement with the U.S. Nuclear Regulatory Commission (NRC), approved the company's treatment, the Alpha DaRT, as a Sealed Source and Device (SSD).